FDA approves Genentech Tecentriq-chemo combo for adjuvant stage III dMMR colon cancer
The FDA approved Genentech’s Tecentriq with fluoropyrimidine plus oxaliplatin for adjuvant treatment of stage III dMMR colon cancer. In the Phase III ATOMIC trial, the regimen reduced recurrence or death by 50%, and 36-month disease-free survival was 86% versus 76% with chemotherapy alone.
1. Trial results
The FDA approval was based on the Phase III ATOMIC trial, which showed a 50% reduction in recurrence or death compared with chemotherapy alone. Three-year disease-free survival was 86% with the combination and 76% with chemotherapy alone; the approval marks Tecentriq’s 12th U.S. indication.
